Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UniVax

Financiado

Cerrado

A Universal Influenza Vaccine through Synthetic Dendritic Cell Targeted Self...

A Universal Influenza Vaccine through Synthetic Dendritic Cell Targeted Self Replicating RNA Vaccines Although vaccination is the cornerstone of prophylaxis, current vaccines provide only moderate protection. Most employ inactivated or protein-based, including multimeric antigen, vaccines requiring annual updating. Their limited a... ver más

30/09/2018

WBF

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

EIDGENOESSISCHES DEPARTEMENT FUER WIRTSCHAFT,... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-09-30 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

WBF

0.00€ | Lider

HVL

N.D. | Participante

MEDITOX

N.D. | Participante

Proyectos interesantes

RNAmpMax

Medical Technol...

Data Science

183K€ Cerrado

HIV INNATE IMMUNITY

Medical Technol...

Data Science

100K€ Cerrado

SAMUFLU

Medical Technol...

Data Science

187K€ Cerrado

DDRR

Medical Technol...

Data Science

185K€ Cerrado

ER and Infection

Medical Technol...

Data Science

183K€ Cerrado

AGL2014-52395-C2-1-R

Medical Technol...

Data Science

Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

EIDGENOESSISCHES DEPARTEMENT FUER WIRTSCHAFT,... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Although vaccination is the cornerstone of prophylaxis, current vaccines provide only moderate protection. Most employ inactivated or protein-based, including multimeric antigen, vaccines requiring annual updating. Their limited antigen loads provide limited capacity for inducing robust immune defences, without assurance that both humoral and cell mediated (CMI) responses, as well as durable immunity, will be induced. Replicating vaccines may provide several rounds of antigen production, increasing potential for humoral and CMI defence induction. Neither live, attenuated nor vector vaccines can be produced synthetically, being reliant on cell culture or egg production. They cannot be targeted to immune cells; interference from pre-existing immunity is also a risk. Efficacious, synthetic vaccines would be the answer, as seen with self-replicating RNA replicon (RepRNA) technology – these replicate and translate without producing infectious progeny. RepRNA produced in vitro is combined with synthetic delivery vehicles targeting dendritic cell (DC) receptors –essential for efficient immune defences– with glycoconjugate ligands. The UniVax project promotes the first synergising of approaches with synthetic targeted delivery systems for RepRNA. The innovation integrates technologies of (i) RepRNA vaccines, (ii) lipoplexes (biodegradable lipid/adjuvant/RNA for cytosolic delivery), (iii) polyplexes (biodegradable, polysaccharide vehicles), (iv) glycoconjugates targeting DC receptors, (v) adjuvants with well-defined molecular targets and effector functions. This promotes efficacious mucosal and systemic responses, ensuring for the first time both humoral and CMI responses. Components developed in PANFLUVAC and Replixcel projects allow UniVax to create the first Universal Flu vaccine prototypes. This innovative approach creates the first synthetic vaccine of its kind, promoting consortium SMEs to a unique position of world leaders.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores